Welcome to our dedicated page for Abcellera Biologics SEC filings (Ticker: ABCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AbCellera Biologics Inc. (Nasdaq: ABCL) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. AbCellera is a clinical-stage biotechnology company focused on antibody-based medicines in endocrinology, women’s health, immunology, and oncology, and its filings offer detailed insight into its financial position, partnered programs, and clinical-stage activities.
Here you can review AbCellera’s current and periodic reports, including Form 8-K filings that disclose material events. Recent 8-Ks have covered topics such as quarterly financial and operational results, the appointment of a Chief Medical Officer, changes to the Board of Directors, and a settlement and patent license agreement with Bruker Corporation that resolved patent litigation globally and provides for upfront and royalty payments. These documents help explain how AbCellera manages leadership transitions, intellectual property matters, and communication of key business milestones.
AbCellera’s filings also identify it as a British Columbia–organized issuer with shares listed on Nasdaq under Commission File Number 001-39781, and they provide definitions of key business metrics such as partner-initiated program starts with downstream participation and molecules in the clinic. Investors can use annual reports on Form 10-K and quarterly reports on Form 10-Q, when available, to analyze revenue from research fees, licensing, and milestone payments, as well as research and development, sales and marketing, and general and administrative expenses.
Stock Titan enhances these SEC documents with AI-powered summaries that highlight important sections, explain technical language, and point out items that may matter to shareholders, such as liquidity, deferred revenue, and deferred government contributions. Users can also monitor Form 4 and related insider transaction reports, along with proxy statements, to better understand executive and director changes and compensation structures. With real-time updates from EDGAR and AI-generated insights, this ABCL filings page helps readers navigate complex regulatory disclosures more efficiently.
AbCellera Biologics Inc. filed an update describing two investor-focused developments. The company has begun dosing the first patients in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635, signaling that this experimental therapy has advanced to the next stage of human testing.
AbCellera also posted an updated corporate presentation on its investor website, which it may use in future communications and conferences. Both the press release about ABCL635 and the new presentation are furnished as exhibits and are not treated as filed financial statements under securities law.
AbCellera Biologics Inc. disclosed that on December 18, 2025 it issued a press release announcing a settlement and patent license agreement with Bruker Corporation. This agreement resolves the patent litigation between the two companies on a global basis, ending the dispute over intellectual property rights worldwide. The press release detailing the settlement and license terms is provided as Exhibit 99.1 to this report, and the information is furnished under Regulation FD rather than filed for liability purposes.
AbCellera Biologics Inc. (ABCL) reported an insider share purchase by a company director. On 11/26/2025, the reporting person bought 50,000 common shares in an open market transaction coded as "P" at a price of $3.5692 per share. After this transaction, the director beneficially owned 221,000 common shares directly.
The filing also notes indirect ownership of an additional 5,000 common shares held by the director’s spouse. The form is filed as a Form 4 for one reporting person and indicates the director relationship to AbCellera Biologics Inc.
AbCellera Biologics Inc. (ABCL) announced Board changes. On November 10, 2025, the Board appointed Stephen Quake, D.Phil., as a director, effective immediately. He will serve until the next annual meeting and has been deemed independent under Nasdaq rules and the Company’s guidelines. Dr. Quake was assigned to the Audit Committee and the Nominating and Corporate Governance Committee and will participate in the Non-Employee Director Compensation Policy on the same terms as other non-employee directors.
Also on November 10, 2025, Andrew Lo, Ph.D., resigned from the Board, effective immediately. The Company stated his resignation was not due to any disagreement. He previously served on the Audit and Nominating and Corporate Governance Committees.
AbCellera Biologics (ABCL) reported a wider quarterly loss while progressing its first proprietary programs into the clinic. For the quarter ended September 30, 2025, revenue was $8.955 million, driven mainly by research fees. Net loss was $57.119 million, or $0.19 per share. For the first nine months of 2025, revenue reached $30.275 million and net loss totaled $137.467 million.
Total cash, cash equivalents, and marketable securities were $495.672 million as of September 30, 2025, compared with $625.614 million at December 31, 2024. Operating expenses fell year over year due to the absence of 2024 impairment charges, though research and development rose to $55.028 million in the quarter as the company advanced internal programs and began clinical activities. AbCellera initiated Phase 1 trials in the second half of 2025 for ABCL635 (vasomotor symptoms) and ABCL575 (OX40L antibody for inflammation) after receiving Health Canada No Objection Letters in May. The company reported 103 partner-initiated programs with downstream participation and 18 molecules in the clinic. Common shares outstanding were 299,335,048 as of November 3, 2025.
AbCellera Biologics Inc. (ABCL) furnished a press release and investor presentation related to its financial and operational results for the quarter ended September 30, 2025. The company aligned the materials with its earnings call on November 6, 2025, and provided them as exhibits.
The information under Items 2.02 and 7.01 is being furnished, not filed, and is not subject to Section 18 liability nor incorporated by reference except as stated. Exhibits include 99.1 (press release) and 99.2 (corporate presentation).
FAQ
What is the current stock price of Abcellera Biologics (ABCL)?
What is the market cap of Abcellera Biologics (ABCL)?
